Heteroconjugate antibodies enhance cell-mediated anti-herpes simplex virus immunity in vivo.
Heteroconjugate antibodies are generated by covalently linking two mAbs with different specificities. When anti-CD3 mAb, capable of activating effector T cells, is coupled to anti-herpes simplex virus (HSV) mAb, which binds HSV antigens on virally-infected target cells, the resulting heteroconjugate antibody can be used in vitro to enhance anti-HSV immunity. Specifically, these heteroconjugate antibodies can augment anti-HSV immunity among lymphocytes previously lacking cytotoxicity against HSV-infected target cells. However, the efficacy of these specialized reagents in enhancing anti-HSV immunity in vivo has not been determined. We report here that anti-HSV heteroconjugates used in an adoptive transfer murine model of HSV-1 infection inhibited HSV replication in vivo and improved long-term survival. These results demonstrate that heteroconjugate antibodies have a potential therapeutic role in enhancement of anti-HSV immunity.
Voss
L M
LM
Department of Immunology, Mayo Clinic, Rochester, MN.
David
C S
CS
Showalter
S D
SD
Paya
C V
CV
Leibson
P J
PJ
D000818:Animals; D000831:Animals, Newborn; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D000914:Antibodies, Viral / Q000008:administration & dosage; D000945:Antigens, Differentiation, T-Lymphocyte; D017252:CD3 Complex; D006561:Herpes Simplex / Q000276:immunology / Q000382:microbiology / Q000628:therapy; D007111:Immunity, Cellular; D051379:Mice; D011948:Receptors, Antigen, T-Cell; D018139:Simplexvirus / Q000276:immunology* / Q000502:physiology; D014779:Virus Replication
D000911:Antibodies, Monoclonal; D000914:Antibodies, Viral; D000945:Antigens, Differentiation, T-Lymphocyte; D017252:CD3 Complex; D011948:Receptors, Antigen, T-Cell